Unigene cuts SDBG to focus gaze on peptides
Peptide-based therapeutics specialists Unigene will focus on high valuation drug development and drug delivery opportunities after cutting loose its Site Directed Bone Growth (SDBG) patent portfolio.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs